Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: A post hoc analysis of SURPASS

Peters, Anne; Buzzetti, Raffaella; Clare, Lee; Pavo, Imre; Liu, Minzhi; Karanikas, Chrisanthi; Paik, Jim

doi:10.5281/zenodo.11454669

Published June 3, 2024 | Version Final

Diagram Open

Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: A post hoc analysis of SURPASS

1. Keck School of Medicine of the University of Southern California
2. Sapienza University of Rome
3. Eli Lilly and Company
4. Tigermed-BCM Inc.

Supplemental appendix of Peters. et al. Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: A post hoc analysis of SURPASS. JCEM 2024.

Files

LADA_JCEM _ZENODO appendix - submitted.pdf

Files (184.4 kB)

Name	Size	Download all
LADA_JCEM _ZENODO appendix - submitted.pdf md5:b5cfcdafbebb92752c37e7638518f522	184.4 kB	Preview Download

Additional details

Eli Lilly (United States)

190

Views

158

Downloads

Show more details

	All versions	This version
Views	190	190
Downloads	158	158
Data volume	33.4 MB	33.4 MB

More info on how stats are collected....

DOI

Resource type

Diagram

Publisher

Zenodo

Published in

The Journal of Clinical Endocrinology & Metabolism, 2024.

License: Creative Commons Attribution 4.0 International

The Creative Commons Attribution license allows re-distribution and re-use of a licensed work on the condition that the creator is appropriately credited. Read more

Technical metadata

Created: June 3, 2024
Modified: June 3, 2024

Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: A post hoc analysis of SURPASS

Authors/Creators

Description

Files

LADA_JCEM _ZENODO appendix - submitted.pdf

Files (184.4 kB)

Additional details

Funding